Status and phase
Conditions
Treatments
About
In stem cell transplantation as treatment for malignant diseases, calcineurin inhibitors like cyclosporine A are commonly used to prevent tissue destruction (GvHD) by activated donor immune cells. The hypothesis for this study is, that replacing calcineurin inhibitors by everolimus and mycophenolate as GvHD prophylaxis not only reduces toxicity of the treatment but also improves tolerance induction of the donor T cells toward the host, eventually increasing the safety of stem cell transplantation.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Diagnosis of hematologic malignancies, indicated for allogeneic stem cell transplantation:
acute myeloid leukemia (AML), in CR1, ≥ CR2, primary refractory, relapse
chronic myeloid leukemia (CML), in chronic phase, in acceleration or blast crisis
myelodysplastic syndrome (MDS), RA/RARS (transfusion dependent), RAEB, RAEB-t and CMML
Lymphoma:
Hodgkins disease
HLA-matched (HLA-A, -B, -DRB1) related or unrelated donor available
Signed informed consent
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
38 participants in 1 patient group
Loading...
Central trial contact
Juergen Finke, MD; Reinhard Marks, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal